Login
Companies $TLPH
$0.86 +$0.00 (0.0%) After hours
TALPHERA, INC. logo

TALPHERA, INC.

talphera.com

What Do They Do?

Develops a regional anticoagulant for hospital dialysis circuits and may develop an intravenous treatment for acute illnesses and ready-to-use syringe medicines for hospitals.

How Do They Make Money?

FY2025 revenue

Who Are Their Customers?

Hospitals are a target market for ready-to-use syringe candidates, which they currently source mainly from compounding facilities or prepare in-house. Talphera is evaluating a potential Niyad launch using its own resources or a commercial partner.

Do Revenues Turn Into Profits?

No. It lost $14.3M in FY2025.

Operating income, FY2025
−48157% of revenue
▲ +12% (Loss) vs FY2024 (−$15.3M)
Net income, FY2025
−51036% of revenue
▼ −10% (Loss) vs FY2024 (−$13M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $1K in Q3 FY2025
Net income
▲ +9% (Loss)
vs −$4.4M in Q3 FY2025

Shrinking. Revenue fell 99% in 4 years, from $2.8M in FY2021 to $28K in FY2025, about 68% a year.

A narrower product focus The older report described nafamostat and pre-filled syringe candidates and a planned DSUVIA divestment. The latest report says resources are focused on Niyad and the syringe candidates may be discontinued.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support